C ritical care pharmacists are recognized in the guidelines from the Society of Critical Care Medicine (SCCM) as essential team members for the delivery of care for critically ill patients. [1] [2] [3] Despite this recognition, a survey conducted in 2004 of 382 US hospitals with an intensive care unit (ICU) found that only 62% had critical care clinical pharmacist services. 4 Even with an increase in critical care medicine beds and costs, 5 this prevalence of ICU clinical pharmacist services was similar to that found in a survey conducted over 15 years prior. 6 The goal of this commentary is to briefly outline the value of critical care pharmacy services through the years, with an emphasis on the possibilities for the future. Excellent, detailed reviews 7-10 and a historical perspective 11 on this topic exist in the literature.
A recent survey of pharmacist services included only 382 of the 3,238 hospitals (11.8%) with an ICU at the time of the survey. 4 The exact number of pharmacists practicing in a critical care environment is not known. There are approximately 1,500 pharmacist members of the SCCM Clinical Pharmacy and Pharmacology Section and about 3,000 critical care pharmacist members as part of the American College of Clinical Pharmacy and the American Society of Health System Pharmacists. This has led to a conservative estimate of 6,000 practicing critical care pharmacists. 12 The time that these pharmacists dedicate to ICU services is unknown. It is projected that the demand for critical care pharmacists will remain stable or grow in the future.
PHARMACISTS' IMPACT ON OUTCOMES: THE PAST
A review article published in 2003 summarized the impact of the critical care pharmacist on clinical, economic, and humanistic outcomes. 10 Data demonstrated that pharmacist involvement improved fluid management, medication error and adverse drug reaction (ADR) frequency, and ventilator-associated pneumonia occurrence. There was a consistent cost-savings associated with pharmacist participation in patient care. Since that time, there have been several more studies evaluating the impact of pharmacists on patient care. We will discuss some of the more recent publications to appreciate the current practice of critical care pharmacists.
PHARMACISTS' IMPACT ON OUTCOMES: THE PRESENT
Pharmacists continue to be an integral member of the intensivist-led patient care team. In fact, several national and international organizations recommend the pharmacist as an active contributor. [1] [2] [3] 13 The roles of critical care pharmacists change, and are even enhanced, over time. 14, 15 Roles have transitioned from dispensing and logistical functions to proactive interventions including ADR prevention. 15, 16 Recent studies (2015-2016) highlighting critical care pharmacist services are summarized in Table 1 .
Role as a Team Member
Clinical pharmacists in the ICU (and in other practice areas) are part of an interprofessional team working toward the common goal of improving patient outcomes. Teams in the ICU often include physicians, pharmacists, nurses, respiratory therapists, dieticians, physical therapists, social workers, and others. Each of these caregivers has a specific role in patient care, and each can contribute positively to patient outcomes. Because interprofessional critical care teams have been shown to benefit patients and their families, integrated team-based care is expressly included in the SCCM-envisioned future statement and guiding principles for the organization and members. 17 The performance of teams is studied in many ways, including team processes. In the ICU, utilization of daily patient-centered goals checklists and commencement of daily multidisciplinary patient care rounds are associated with positive patient outcomes. [18] [19] [20] [21] [22] Improving team interactions has been associated with positive patient outcomes, and poor 
Clinical Outcomes
Compared to previous publications (prior to 2003) evaluating critical care pharmacist services, more recent evaluations include specialty ICUs, international institutions, and an expansion of pharmacist activities. 14, 15, [25] [26] [27] The impact of pharmacist services on medication safety and infectious disease-related outcomes continues to be a focus. This seems highly reasonable due to pharmacist involvement in appropriate prescribing and antibiotic management. It is expected that these activities will continue and even expand in the future. Recent data delve further into the significance of pharmacist interventions, with about 20% considered high-impact and 3% preventing harm or life-threatening circumstances. 15, 26, 27 
Economic Outcomes
One of the obstacles to initiating ICU pharmacy services (or even increasing the number of ICU clinical pharmacists) is securing the necessary salary support. Pharmacist salaries often exceed those of other allied health providers, such as nurse practitioners or physician assistants, who can bill for their services. At present, pharmacists must demonstrate their economic value through cost avoidance (either through direct drug cost savings or prevention of adverse events) and not revenue generation. This is further complicated by the fact that the benefits realized (such as a decrease in duration of mechanical ventilation or ICU length of stay) may be attributed to a department other than pharmacy. 9 As such, it is often a leap of faith for hospital administrators to believe that a critical care clinical pharmacist will create a positive return on investment.
The economic benefits of critical care pharmacy services are demonstrated in a number of studies. [28] [29] [30] [31] [32] In fact, the return on investment of an ICU pharmacist's salary approached a multiple of 25 in a study of critically ill patients with infection. 30 The investigators further noted that the economic benefit of pharmacists is underestimated because the costs avoided did not account for a potential decreased mortality or shortened length of ICU stay. 9, 30 Moreover, in a recent survey, prescribers generally perceived greater clinical and financial impact of direct critical care pharmacy services than the pharmacist who provided these services. 33 As such, the leap of faith that administrators must take to justify critical care pharmacy services is worthwhile both financially and based on prescriber perceptions.
Patient-Reported Outcomes
There continues to be a lack of data on the impact of pharmacist care on humanistic outcomes, more recently referred to as patient-reported outcomes. 10 This may be due to the difficulty of isolating the influence of the pharmacist's activities as part of an interprofessional team on quality of life. A more realistic approach may be to assess patient and family satisfaction with specific care elements. For example, satisfaction with sedation in the ICU from a patient's perspective can be improved. 34 
FUTURE IMPACT ON OUTCOMES Medication Error and ADE Prevention
Incorporation of a clinical pharmacist into an interprofessional rounding team in the ICU is associated with a reduction in preventable adverse drug events (ADEs), patient length of stay, and costs. 28, 31, 35 The future of medication safety prevention activities will include optimizing the use of technology. The use of clinical decision support will move from detection of ADEs to prevention by way of incorporating new diagnostics (biomarkers), risk prediction models, and more sophisticated alert programming. 36 
Working with Patients and Their Families
Patients and their families are being encouraged to participate in the patient's care. 37 Communication with patients and their families in the ICU will continue to increase as families are being engaged in activities such as ICU team rounds. Families participating in patient care rounds for pediatric patients frequently initiated discussions of medications. 38 There is a movement toward asking patients and families about the development of suspected adverse drug reactions (ADRs). 39, 40 This is not frequently addressed in the ICU, but it is likely to be a future activity. Also, family participation in delirium prevention to avoid pharmacologic treatment is undergoing current consideration. 41 Enhancing patient and Volume 51, July-August 2016 family communication will result in greater satisfaction with care and a mitigation of ADR frequency and severity.
Transitions of Care
There is an initiative that has grown in SCCM that is called THRIVE. It is the response to the idea that the needs of ICU survivors are not being met and health care practitioners need to fill this void. 42 There is encouragement of survivor partnerships to optimize recovery. One step to achieve better outcomes is through improved care coordination. This is an ideal opportunity for pharmacist involvement as part of the team to reconcile medications from the ICU to ward and/or after hospital discharge. It is known that drugs, such as stress ulcer prophylaxis and antipsychotics for ICU delirium treatment, are prescribed beyond the needed duration, increasing costs and possibly ADRs. [43] [44] [45] The focus of drug therapy management following the ICU stay could emphasize highrisk medications discussed in the US Department of Health and Human Services National Action Plan for Adverse Drug Event Prevention. 46 High-risk drugs include anticoagulants, antidiabetic agents, and opioids; nephrotoxins may be worth adding. Identifying drug problems that need to be managed could appropriately increase care coordination between hospital and community pharmacists. In a post-ICU care clinic, in addition to a thorough medication reconciliation, the pharmacist can evaluate ADRs and medication nonadherence. 47 Post-ICU care clinics have been initiated at a handful of institutions and are likely to continue to grow. 47 The future of post-ICU clinics may include fewer face-to-face interactions and more telemedicine communications. 48 It is hoped that the outcomes achieved by this expanded service will be better prescribing and monitoring, resulting in a reduction in medication errors, ADRs, and hospital readmissions and better medication adherence.
Quality and Process Measure Improvement Efforts
ICU-related quality and process measures will continue to be emphasized because of their impact on patient-centered outcomes and institutional reimbursement. Sedative administration is associated with prolonged duration of mechanical ventilation, which in turn has been connected to ventilator-associated events (eg, ventilator-associated pneumonia). Improving sedation management in the ICU is a focus of many quality improvement efforts. A pharmacist-led quality initiative increased the process measures surrounding spontaneous awakening and breathing trials, 49 an important component of sedation management. A similar improvement in the performance of spontaneous awakening trials was observed with the addition of a nighttime tele-ICU pharmacist. 50 Furthermore, appointing a clinical pharmacist to enforce a sedation protocol was associated with a decrease in duration of mechanical ventilation, ICU length of stay, and hospital length of stay. 51 In light of these data, critical care pharmacists may be increasingly charged with sedation management in mechanically ventilated patients.
Severe sepsis and septic shock is another ICUrelated quality measure that was recently initiated. Because it is complex and challenging to meet this measure, pharmacists can play a vital role. 52 The involvement of pharmacists in the identification and treatment of patients with sepsis has previously been demonstrated to improve patient outcomes. 25, 53 As such, it is likely that pharmacist involvement in the care of patients with sepsis will also translate to increased quality measure compliance and further improvements in patient outcomes. Additionally, the value of pharmacists has been demonstrated for multiple ICU-related process measures, such as decreasing inappropriate stress ulcer prophylaxis continuation 43 and preventing QTc interval prolongation. 54 Pharmacists are well positioned to lead and contribute to quality and process measure improvement efforts in the future.
Medication Dosing in Specialty Populations
One opportunity for pharmacists to maximize their value would be to contribute to dosing in specialty populations in the ICU, such as patients undergoing therapeutic hypothermia, treated with extracorporeal devices (extracorporeal membrane oxygenation, continuous renal replacement therapy, molecular adsorbent recirculating system, etc), with obesity, or with end-organ dysfunction (eg, acute kidney insufficiency or end-stage liver disease). Pharmacists can provide specific dosing services (such as those previously described for obese patients 55 or those treated with continuous renal replacement therapy 56 ) or lead research regarding optimal dosing approaches in these patient populations. 57 Because of their knowledge of pharmacokinetic/pharmacodynamic parameters and the potential impact of these parameters on patient-centered outcomes, pharmacists are ideally suited to lead the effort to optimize medication dosing in these or other specialty populations that arise in the future.
Pharmacist Prescribing
It is possible that pharmacist functions such as order verification and algorithmic-type medication selection will become more automated. Some critical care pharmacists want to become independent prescribers. 58 It has already been permitted in countries such as the United Kingdom. Prescribing authority includes dose adjustment in patients with organ failure, change in route of drug administration, correction of medication errors, and therapeutic drug monitoring. Alberta was the first province in Canada to approve independent prescribing for pharmacists. 59 We are seeing extended services such as drug ordering and monitoring by clinical pharmacist practitioners in ICUs in the United States. 14 The role of the pharmacist as an independent prescriber is becoming a reality and will likely continue to grow, which may result in improved prescribing with better accuracy.
Further Research Is Needed
Although ICU pharmacists have been shown to have an impact in multiple studies, their benefit has not been universal. Indeed, in 2 systematic reviews and meta-analyses, pharmacist involvement was not independently associated with a reduction in overall medication errors. 60, 61 One study found a benefit for pharmacists in reducing preventable adverse drug events, but the negative overall findings were driven by another study 62 showing an increase in medication errors with pharmacist involvement. The quality of evidence was determined to be low, and all included studies were considered a high risk for bias due to a lack of adjustment for potential confounders. 61 Although there may be ethical challenges in setting up these studies, future high-quality studies of the impact of critical care pharmacists, such as the design employed by Claus et al, 63 are needed. Additionally, optimal ICU pharmacist functions, patientto-pharmacist ratios, and staffing models should be investigated. High-quality studies are necessary to demonstrate the value of critical care pharmacists to regulatory agencies (such as Centers for Medicare & Medicaid Services and The Joint Commission) and to solidify the role of the critical care pharmacist as a vital member of the interprofessional team.
CONCLUSIONS
Evaluations of critical care pharmacist services have expanded to include specialty ICUs and international institutions, suggesting that the value of these activities is recognized. There is evidence that critical care pharmacist interventions have a high impact on outcomes and can prevent lifethreatening situations. The duration that a pharmacist functions as part of a patient care team may result in enhanced clinical activities. Future pharmacist services may include working more with patients and their families, becoming more involved in transitions of care, leading the improvement in quality indicators, optimizing dosing in specialty populations, and taking advantage of independent prescribing capabilities. As pharmacist activities expand, the need for well-designed outcomes studies is essential.
